Abstract Library

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4430 Long-term prognosis of parenchyma-sparing vs. oncologic resections for distal pancreatic non-functional neuroendocrine tumours ≤ 3cm: A real-world data study (CSPAC-NEN-5)

Introduction: Studies show that parenchyma-sparing resections (PSR) for small, non-functional pancreatic neuroendocrine tumours (NF-pNETs) provide long-term outcomes similar to oncologic resections (OR). However, these studies have not fully considered location-based differences in surgical approach and lymphatic drainage.

Conference:

Presenting Author: Li Z

Authors: Li Z, Ji S, Chen J, Xu X, Yu X,

Keywords: pancreatic neuroendocrine, parenchyma-sparing resection, recurrence-free survival,

#4374 Efficacy and safety of immunotherapy combined with antiangiogenesis agents and temozolomide in neuroendocrine carcinoma

Introduction: Platinum-based doublet chemotherapy is the standard first-line treatment, without standard treatment for second-line or subsequent systemic therapy for recurrent or progressive advanced neuroendocrine cancer (NEC).

Conference:

Presenting Author:

Authors: Li X, Yang M, Fan Q, Song L,

Keywords: Neuroendocrine carcinoma, Immunotherapy, Antiangiogenesis agents, Temozolomide,

#4318 Management of asymptomatic, sporadic, small non-functional pancreatic neuroendocrine tumours: Active surveillance or surgery? A retrospective cohort study in the SEER database

Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) exhibit a wide heterogeneity of aggressiveness and optimal management of asymptomatic, sporadic, small PanNETs remains controversial.

Conference:

Presenting Author: Chen C

Authors: Chen C, Zheng Z, Li P, Hu H,

Keywords: Pancreatic neuroendocrine tumour, surveillance, surgery, prognosis, SEER,

#4316 Combination of sorafenib and everolimus regresses pancreatic neuroendocrine tumour significantly in vitro and vivo

Introduction: PNET is a rare group of highly heterogeneous tumours with neuroendocrine differentiation properties. Everolimus is the most promising drug for progressive well-differentiated pNETs. Sorafenib's anti-tumour activity may involve regulation of the mTOR pathway.

Conference:

Presenting Author: Zheng H

Authors: Zheng H,

Keywords: sorafenib, everolimus, pancreatic neuroendocrine tumour, mTOR,